Manufacturing: Page 9


  • Pfizer, BioNTech in final talks to supply EU with coronavirus vaccine

    The companies, which are among the furthest along in testing, would deliver up to 300 million doses of their shot to EU countries under a proposed deal.

    By Kristin Jensen • Sept. 9, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA scolds Mylan for 'repeated' manufacturing problems

    Though it once had a glimmering manufacturing record, Mylan now finds itself in the crosshairs of the FDA. The agency is advising the company to quickly and comprehensively assess its global operations.

    By Updated Sept. 4, 2020
  • Catalent, seeing rising demand, to expand Indiana production plant

    The planned $50 million infusion is the third investment in Catalent's Bloomington facility in two years, reflecting the need for vial filling for biologic drugs and vaccines.

    By Kristin Jensen • Sept. 3, 2020
  • Vials of an experimental coronavirus vaccine developed by CanSino Biologics
    Image attribution tooltip
    Courtesy of CanSino Biologics
    Image attribution tooltip

    CanSino, Canada abandon plans for a coronavirus vaccine trial

    Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study.

    By Kristin Jensen • Aug. 27, 2020
  • AstraZeneca broadens coronavirus vaccine manufacturing deal with Catalent

    Catalent, which is already helping the British pharma make its vaccine, will now add key services from a Maryland gene therapy plant.

    By Kristin Jensen • Aug. 26, 2020
  • Image attribution tooltip
    Moderna
    Image attribution tooltip

    Moderna joins other vaccine leaders in European supply talks

    The deal would designate up to 160 million doses of Moderna's shot for the European Union, which has worked aggressively of late to bolster its supply.  

    By Aug. 24, 2020
  • A transmission electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
    Image attribution tooltip

    CureVac in talks to supply EU with coronavirus vaccine

    A deal being negotiated would provide EU countries with 225 million doses of CureVac's experimental shot, which relies on similar technology as those developed by Moderna and BioNTech. 

    By Kristin Jensen • Aug. 20, 2020
  • Image attribution tooltip
    Regeneron
    Image attribution tooltip

    Regeneron enlists Roche to boost production of COVID-19 antibody drug

    Together, the companies expect they can make more than three times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own.

    By Kristin Jensen • Aug. 19, 2020
  • Europe, trailing US, UK, reaches first coronavirus vaccine deal

    Both the U.S. and U.K. have aggressively signed preorder deals with vaccine developers. An agreement with AstraZeneca is the EU's first. 

    By Aug. 14, 2020
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient.
    Image attribution tooltip
    National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Argentina, Mexico line up to produce AstraZeneca, Oxford coronavirus vaccine

    The manufacturing deal could help supply Latin America with Oxford's shot, which is one of the most advanced in clinical testing.

    By Kristin Jensen • Aug. 13, 2020
  • Image attribution tooltip
    Eastman Business Park/Courtesy of Eastman Kodak Company
    Image attribution tooltip

    US puts Kodak loan on hold after stock scrutiny

    Lawmakers questioned the timing of stock options granted to Kodak executives a day before the planned $765 million loan was announced. An SEC investigation is reportedly underway.

    By Aug. 10, 2020
  • Capping of investigational remdesivir vials, photo by Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Pfizer to help Gilead produce COVID-19 drug remdesivir

    With supplies of the in-demand drug tight, Gilead has enlisted Pfizer, along with companies across the globe, to churn out millions of treatment courses.

    By Aug. 7, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Trump tries to revamp drug supply chain with latest order

    A directive announced by the president would require government agencies to buy certain "essential" drugs from factories in the U.S. How easily such an order would be implemented isn't clear.

    By Aug. 6, 2020
  • This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
    Image attribution tooltip

    India's role in coronavirus vaccine manufacturing grows with new deals

    The Serum Institute, one of the world's largest vaccine producers, licensed Novavax's experimental shot, while Wockhardt signed on with the U.K. to help make AstraZeneca's candidate.

    By Kristin Jensen • Aug. 6, 2020
  • FujiFilm 2,000-litre mammalian cell culture tank
    Image attribution tooltip
    Courtesy of FujiFilm
    Image attribution tooltip

    US taps camera makers for help manufacturing drugs, vaccines

    The Trump administration plans to loan Kodak $765 million to produce drug ingredients, one day after enlisting Fujifilm to help make coronavirus vaccines.

    By July 28, 2020
  • Kundl manufacturing site in Austria.
    Image attribution tooltip
    Retrieved from Sandoz on July 27, 2020
    Image attribution tooltip

    Sandoz earmarks $175M to upgrade tech at European hub for antibiotics manufacturing

    About a third of the money will come from the Austrian government and be put toward technology used to make the active ingredients in penicillin products.

    By July 27, 2020
  • This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565892277/in/album-72157713108522106/.
    Image attribution tooltip

    UK to spend almost $130M more on coronavirus vaccine manufacturing

    The investment will upgrade a Cell and Gene Therapy Catapult site so it can manufacture coronavirus vaccines and respond to future pandemics.

    By July 23, 2020
  • Thermo Fisher rakes in $1.3B in coronavirus-related revenue

    The second quarter saw the company's diagnostic and healthcare end market sales jump more than 70% due to soaring demand for COVID-19 testing.

    By Nick Paul Taylor • July 22, 2020
  • Ventec ventilator being worked on at GM's retooled parts plant in Kokomo, Indiana.
    Image attribution tooltip
    Courtesy of https://ventecgm.com/
    Image attribution tooltip

    An insider's look at how GM, Ventec ramped up ventilator production amid COVID-19

    The weight of the Defense Production Act helped open doors, said the CEO of the engineering firm contracted to test each of the 30,000 devices expected under the agreement.

    By Greg Slabodkin • July 13, 2020
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Civica enlists Novartis to produce generic injectable drugs

    Founded by hospital systems to address drug shortages, the nonprofit group has now struck several partnerships to expand its network of suppliers.

    By Kristin Jensen • July 9, 2020
  • Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US buys up early supply of Regeneron's COVID-19 antibody cocktail

    A $450 million grant will help Regeneron scale up manufacturing of its drug, which is among the front-running antibody therapies for COVID-19.

    By July 7, 2020
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation
    Image attribution tooltip

    Novavax gets $1.6B in US funding for coronavirus vaccine

    The funding will secure 100 million doses of Novavax's experimental shot, which is set to begin late-stage testing this fall.

    By July 7, 2020
  • Image attribution tooltip
    Janssen
    Image attribution tooltip

    J&J, with new deal, plans for long-term manufacture of coronavirus vaccine

    A five-year agreement with Maryland's Emergent Biosolutions will provide for large-scale production of J&J's candidate, set to begin testing in July.

    By July 6, 2020
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Novartis cancer drug unit to build Indianapolis factory

    Advanced Accelerator Applications, a subsidiary of the Swiss pharma, will build a new site to produce targeted radioligand therapies like Lutathera.

    By Kristin Jensen • July 2, 2020
  • A volunteer in a clinical trial is dosed with BNT162, an experimental coronavirus vaccine developed by Pfizer and BioNTech
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses

    More than $18 billion will be needed for the WHO's plan, which would secure and allocate vaccine supplies for high-risk groups and lower-income countries.

    By June 26, 2020